[English] 日本語
Yorodumi- EMDB-47393: Structure of RyR1 in the primed state in the presence of oxypurinol -
+
Open data
-
Basic information
| Entry | ![]() | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Title | Structure of RyR1 in the primed state in the presence of oxypurinol | |||||||||
Map data | Structure of RyR1 in the primed state in the presence of oxypurinol | |||||||||
Sample |
| |||||||||
Keywords | calcium channel / TRANSPORT PROTEIN / sarcoplasmic reticulum | |||||||||
| Function / homology | Function and homology informationcytoplasmic side of membrane / ATP-gated ion channel activity / terminal cisterna / ryanodine receptor complex / ryanodine-sensitive calcium-release channel activity / release of sequestered calcium ion into cytosol by sarcoplasmic reticulum / ossification involved in bone maturation / cellular response to caffeine / skin development / organelle membrane ...cytoplasmic side of membrane / ATP-gated ion channel activity / terminal cisterna / ryanodine receptor complex / ryanodine-sensitive calcium-release channel activity / release of sequestered calcium ion into cytosol by sarcoplasmic reticulum / ossification involved in bone maturation / cellular response to caffeine / skin development / organelle membrane / intracellularly gated calcium channel activity / smooth endoplasmic reticulum / outflow tract morphogenesis / regulation of ryanodine-sensitive calcium-release channel activity / toxic substance binding / striated muscle contraction / voltage-gated calcium channel activity / skeletal muscle fiber development / regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum / release of sequestered calcium ion into cytosol / sarcoplasmic reticulum membrane / muscle contraction / cellular response to calcium ion / sarcoplasmic reticulum / peptidylprolyl isomerase / peptidyl-prolyl cis-trans isomerase activity / sarcolemma / calcium ion transmembrane transport / calcium channel activity / Z disc / intracellular calcium ion homeostasis / disordered domain specific binding / protein homotetramerization / transmembrane transporter binding / calmodulin binding / intracellular membrane-bounded organelle / calcium ion binding / ATP binding / identical protein binding / membrane / cytosol Similarity search - Function | |||||||||
| Biological species | ![]() | |||||||||
| Method | single particle reconstruction / cryo EM / Resolution: 3.17 Å | |||||||||
Authors | Miotto MC / Marks AR | |||||||||
| Funding support | 1 items
| |||||||||
Citation | Journal: Proc Natl Acad Sci U S A / Year: 2025Title: Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders. Authors: Marco C Miotto / Estefania Luna-Figueroa / Carl Tchagou / Laith Bahlouli / Steven Reiken / Haikel Dridi / Yang Liu / Gunnar Weninger / Andrew R Marks / ![]() Abstract: Ryanodine receptors (RyRs) are intracellular Ca channels essential for muscle contraction. Caffeine, a xanthine derivative, has been known for decades to increase muscle contraction and enhance ...Ryanodine receptors (RyRs) are intracellular Ca channels essential for muscle contraction. Caffeine, a xanthine derivative, has been known for decades to increase muscle contraction and enhance activation of RyRs by increasing the sensitivity to Ca. We previously showed that xanthine, the only physiologically relevant xanthine derivative, also binds to and activates RyR2. Most xanthine derivatives and analogs are safe and widely prescribed, with the most popular being the xanthine oxidoreductase inhibitor allopurinol (~15M yearly prescriptions in USA). We propose that xanthine derivatives and analogs that enhance RyRs activity could be used for lead optimization and eventually for the treatment of the diseases that exhibit decreased muscle contraction and reduced RyRs activity, such as RyR1-related diseases, sarcopenia, and heart failure. Here, we show by cryo-EM that xanthine derivatives, analogs, and other related compounds bind to the xanthine/caffeine binding site and activate RyR1, and identify 4-oxopyrimidine as the minimal motif necessary for such interaction. | |||||||||
| History |
|
-
Structure visualization
| Supplemental images |
|---|
-
Downloads & links
-EMDB archive
| Map data | emd_47393.map.gz | 255.1 MB | EMDB map data format | |
|---|---|---|---|---|
| Header (meta data) | emd-47393-v30.xml emd-47393.xml | 30.7 KB 30.7 KB | Display Display | EMDB header |
| Images | emd_47393.png | 133.9 KB | ||
| Filedesc metadata | emd-47393.cif.gz | 9.9 KB | ||
| Others | emd_47393_additional_1.map.gz emd_47393_half_map_1.map.gz emd_47393_half_map_2.map.gz | 257.1 MB 474.9 MB 474.9 MB | ||
| Archive directory | http://ftp.pdbj.org/pub/emdb/structures/EMD-47393 ftp://ftp.pdbj.org/pub/emdb/structures/EMD-47393 | HTTPS FTP |
-Validation report
| Summary document | emd_47393_validation.pdf.gz | 1.2 MB | Display | EMDB validaton report |
|---|---|---|---|---|
| Full document | emd_47393_full_validation.pdf.gz | 1.2 MB | Display | |
| Data in XML | emd_47393_validation.xml.gz | 18.8 KB | Display | |
| Data in CIF | emd_47393_validation.cif.gz | 22.5 KB | Display | |
| Arichive directory | https://ftp.pdbj.org/pub/emdb/validation_reports/EMD-47393 ftp://ftp.pdbj.org/pub/emdb/validation_reports/EMD-47393 | HTTPS FTP |
-Related structure data
| Related structure data | ![]() 9e1gMC ![]() 9e17C ![]() 9e18C ![]() 9e19C ![]() 9e1aC ![]() 9e1bC ![]() 9e1cC ![]() 9e1dC ![]() 9e1eC ![]() 9e1fC ![]() 9e1hC ![]() 9e1iC M: atomic model generated by this map C: citing same article ( |
|---|---|
| Similar structure data | Similarity search - Function & homology F&H Search |
-
Links
| EMDB pages | EMDB (EBI/PDBe) / EMDataResource |
|---|---|
| Related items in Molecule of the Month |
-
Map
| File | Download / File: emd_47393.map.gz / Format: CCP4 / Size: 512 MB / Type: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | Structure of RyR1 in the primed state in the presence of oxypurinol | ||||||||||||||||||||||||||||||||||||
| Projections & slices | Image control
Images are generated by Spider. | ||||||||||||||||||||||||||||||||||||
| Voxel size | X=Y=Z: 0.8365 Å | ||||||||||||||||||||||||||||||||||||
| Density |
| ||||||||||||||||||||||||||||||||||||
| Symmetry | Space group: 1 | ||||||||||||||||||||||||||||||||||||
| Details | EMDB XML:
|
-Supplemental data
-Additional map: Structure of RyR1 in the primed state in...
| File | emd_47393_additional_1.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | Structure of RyR1 in the primed state in the presence of oxypurinol - focused map | ||||||||||||
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-Half map: #1
| File | emd_47393_half_map_1.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-Half map: #2
| File | emd_47393_half_map_2.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-
Sample components
+Entire : Complex of RyR1 and Calstabin-1
+Supramolecule #1: Complex of RyR1 and Calstabin-1
+Supramolecule #2: Ryanodine Receptor 1
+Supramolecule #3: Calstabin-1
+Macromolecule #1: Ryanodine receptor 1
+Macromolecule #2: Peptidyl-prolyl cis-trans isomerase FKBP1A
+Macromolecule #3: ADENOSINE-5'-TRIPHOSPHATE
+Macromolecule #4: CALCIUM ION
+Macromolecule #5: ZINC ION
+Macromolecule #6: Oxypurinol
+Macromolecule #7: water
-Experimental details
-Structure determination
| Method | cryo EM |
|---|---|
Processing | single particle reconstruction |
| Aggregation state | particle |
-
Sample preparation
| Concentration | 10 mg/mL | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buffer | pH: 7.4 Component:
Details: 2 mM oxypurinol was added to the final sample from a 100 mM stock solution in 100% DMSO. | |||||||||||||||||||||||||||
| Vitrification | Cryogen name: ETHANE / Instrument: FEI VITROBOT MARK IV |
-
Electron microscopy
| Microscope | TFS KRIOS |
|---|---|
| Temperature | Min: 80.0 K / Max: 100.0 K |
| Specialist optics | Energy filter - Name: GIF Bioquantum / Energy filter - Slit width: 20 eV |
| Image recording | Film or detector model: GATAN K3 BIOQUANTUM (6k x 4k) / Digitization - Dimensions - Width: 5760 pixel / Digitization - Dimensions - Height: 4092 pixel / Average electron dose: 58.0 e/Å2 |
| Electron beam | Acceleration voltage: 300 kV / Electron source: FIELD EMISSION GUN |
| Electron optics | C2 aperture diameter: 100.0 µm / Illumination mode: FLOOD BEAM / Imaging mode: BRIGHT FIELD / Cs: 2.7 mm / Nominal defocus max: 1.5 µm / Nominal defocus min: 0.5 µm |
| Sample stage | Specimen holder model: FEI TITAN KRIOS AUTOGRID HOLDER / Cooling holder cryogen: NITROGEN |
| Experimental equipment | ![]() Model: Titan Krios / Image courtesy: FEI Company |
Movie
Controller
About Yorodumi



Keywords
Authors
Citation





































Z (Sec.)
Y (Row.)
X (Col.)















































Processing
FIELD EMISSION GUN

